241 related articles for article (PubMed ID: 36588876)
1. Progressive multifocal leukoencephalopathy genetic risk variants for pharmacovigilance of immunosuppressant therapies.
Hatchwell E; Smith EB; Jalilzadeh S; Bruno CD; Taoufik Y; Hendel-Chavez H; Liblau R; Brassat D; Martin-Blondel G; Wiendl H; Schwab N; Cortese I; Monaco MC; Imberti L; Capra R; Oksenberg JR; Gasnault J; Stankoff B; Richmond TA; Rancour DM; Koralnik IJ; Hanson BA; Major EO; Chow CR; Eis PS
Front Neurol; 2022; 13():1016377. PubMed ID: 36588876
[TBL] [Abstract][Full Text] [Related]
2. Germline Genetic Risk Variants for Progressive Multifocal Leukoencephalopathy.
Eis PS; Bruno CD; Richmond TA; Koralnik IJ; Hanson BA; Major EO; Chow CR; Hendel-Chavez H; Stankoff B; Gasnault J; Taoufik Y; Hatchwell E
Front Neurol; 2020; 11():186. PubMed ID: 32256442
[TBL] [Abstract][Full Text] [Related]
3. Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.
Wijburg MT; Kleerekooper I; Lissenberg-Witte BI; de Vos M; Warnke C; Uitdehaag BMJ; Barkhof F; Killestein J; Wattjes MP
JAMA Neurol; 2018 Jul; 75(7):827-833. PubMed ID: 29532061
[TBL] [Abstract][Full Text] [Related]
4. Progressive multifocal leukoencephalopathy in anti-CD20 and other monoclonal antibody (mAb) therapies used in multiple sclerosis: A review.
Sharma K; Tolaymat S; Yu H; Elkhooly M; Jaiswal S; Jena A; Kakara M; Sriwastava S
J Neurol Sci; 2022 Dec; 443():120459. PubMed ID: 36283150
[TBL] [Abstract][Full Text] [Related]
5. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies.
Ho PR; Koendgen H; Campbell N; Haddock B; Richman S; Chang I
Lancet Neurol; 2017 Nov; 16(11):925-933. PubMed ID: 28969984
[TBL] [Abstract][Full Text] [Related]
6. Immune System Involvement in the Pathogenesis of JC Virus Induced PML: What is Learned from Studies of Patients with Underlying Diseases and Therapies as Risk Factors.
Monaco MC; Major EO
Front Immunol; 2015; 6():159. PubMed ID: 25972864
[TBL] [Abstract][Full Text] [Related]
7. Probable progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with immunosuppressant dose reduction following lung transplantation: a case report and literature review.
Ishii K; Yamamoto F; Homma S; Okada Y; Nakamichi K; Saijo M; Tamaoka A
BMC Neurol; 2019 Oct; 19(1):263. PubMed ID: 31672142
[TBL] [Abstract][Full Text] [Related]
8. Progressive multifocal leukoencephalopathy and rheumatoid arthritis treatments.
Clavel G; Moulignier A; Semerano L
Joint Bone Spine; 2017 Dec; 84(6):671-675. PubMed ID: 28323224
[TBL] [Abstract][Full Text] [Related]
9. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Plavina T; Subramanyam M; Bloomgren G; Richman S; Pace A; Lee S; Schlain B; Campagnolo D; Belachew S; Ticho B
Ann Neurol; 2014 Dec; 76(6):802-12. PubMed ID: 25273271
[TBL] [Abstract][Full Text] [Related]
10. Human polyomavirus JC reactivation and pathogenetic mechanisms of progressive multifocal leukoencephalopathy and cancer in the era of monoclonal antibody therapies.
Bellizzi A; Nardis C; Anzivino E; Rodìo D; Fioriti D; Mischitelli M; Chiarini F; Pietropaolo V
J Neurovirol; 2012 Feb; 18(1):1-11. PubMed ID: 22290500
[TBL] [Abstract][Full Text] [Related]
11. Early reduction of the splicing factor2/alternative splicing factor: a cellular inhibitor of the JC polyomavirus in natalizumab-treated MS patients long before developing progressive multifocal leukoencephalopathy.
Piu C; Ibba G; Bertoli D; Capra R; Uleri E; Serra C; Imberti L; Dolei A
J Neurovirol; 2020 Feb; 26(1):133-137. PubMed ID: 31468472
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab for the treatment of Progressive Multifocal Leukoencephalopathy (PML) in a patient with AIDS: A case report and literature review.
Chatterjee T; Roy M; Lin RC; Almoujahed MO; Ahmad S
IDCases; 2022; 28():e01514. PubMed ID: 35637642
[TBL] [Abstract][Full Text] [Related]
13. Considerations on the appropriateness of the John Cunningham virus antibody assay use in patients with rheumatoid arthritis.
Borie D; Kremer JM
Semin Arthritis Rheum; 2015 Oct; 45(2):163-6. PubMed ID: 26190565
[TBL] [Abstract][Full Text] [Related]
14. A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy.
Du Pasquier RA; Kuroda MJ; Zheng Y; Jean-Jacques J; Letvin NL; Koralnik IJ
Brain; 2004 Sep; 127(Pt 9):1970-8. PubMed ID: 15215217
[TBL] [Abstract][Full Text] [Related]
15. A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification.
Lee P; Plavina T; Castro A; Berman M; Jaiswal D; Rivas S; Schlain B; Subramanyam M
J Clin Virol; 2013 Jun; 57(2):141-6. PubMed ID: 23465394
[TBL] [Abstract][Full Text] [Related]
16. Monitoring the John Cunningham virus throughout natalizumab treatment in multiple sclerosis patients.
Domínguez-Mozo MI; García-Montojo M; Arias-Leal A; García-Martínez Á; Santiago JL; Casanova I; Galán V; Arroyo R; Fernández-Arquero M; Alvarez-Lafuente R
Eur J Neurol; 2016 Jan; 23(1):182-9. PubMed ID: 26498276
[TBL] [Abstract][Full Text] [Related]
17. JC virus infection of meningeal and choroid plexus cells in patients with progressive multifocal leukoencephalopathy.
Corbridge SM; Rice RC; Bean LA; Wüthrich C; Dang X; Nicholson DA; Koralnik IJ
J Neurovirol; 2019 Aug; 25(4):520-524. PubMed ID: 31025264
[TBL] [Abstract][Full Text] [Related]
18. Changes to anti-JCV antibody levels in a Swedish national MS cohort.
Warnke C; Ramanujam R; Plavina T; Bergström T; Goelz S; Subramanyam M; Kockum I; Rahbar A; Kieseier BC; Holmén C; Olsson T; Hillert J; Fogdell-Hahn A
J Neurol Neurosurg Psychiatry; 2013 Nov; 84(11):1199-205. PubMed ID: 23463870
[TBL] [Abstract][Full Text] [Related]
19. Modeling probability of additional cases of natalizumab-associated JCV sero-negative progressive multifocal leukoencephalopathy.
Carruthers RL; Chitnis T; Healy BC
Mult Scler; 2014 May; 20(6):757-60. PubMed ID: 24189572
[TBL] [Abstract][Full Text] [Related]
20. Investigation of pre-diagnostic virological markers for progressive multifocal leukoencephalopathy in human immunodeficiency virus-infected patients.
Grabowski MK; Viscidi RP; Margolick JB; Jacobson LP; Shah KV
J Med Virol; 2009 Jul; 81(7):1140-50. PubMed ID: 19475619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
